News

Argent BioPharma Unveils Breakthrough Therapy for Inflammations

Argent BioPharma Unveils Breakthrough Therapy for Inflammations

Argent BioPharma Expands Pipeline with Promising Drug CimetrA®

Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a leader in clinical-stage biopharmaceutical innovations, is proud to announce significant advancements in its drug development pipeline. The company has recently completed a Phase IIb clinical trial of CimetrA®, an innovative anti-inflammatory treatment aimed at addressing crucial medical needs in various inflammatory diseases.

Positive Clinical Trial Results

The Phase IIb trial demonstrated remarkable results, showcasing the efficacy and safety of CimetrA®. One of the most encouraging findings was the absence of drug-related adverse events, affirming CimetrA®'s robust safety profile. Participants who received the treatment showed faster clinical improvement, significantly outpacing those on a placebo as per the World Health Organization Ordinal Scale.

Moreover, the treatment resulted in a notable reduction in inflammation levels, evidenced by significant modulation of essential inflammatory markers such as IL-6, IL-1?, and TNF-?. Patients treated with CimetrA® also reported improvements in quality of life, indicating the therapy's potential to provide substantial benefits to individuals suffering from inflammatory conditions.

Insights from Leadership

Roby Zomer, the CEO of Argent BioPharma, expressed enthusiasm regarding the trial's results. He mentioned, "These promising results highlight CimetrA®'s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development." This statement underscores the company’s commitment to bringing cutting-edge therapies to market, further enhancing patient care.

Comprehensive Therapeutic Portfolio

In addition to CimetrA®, Argent BioPharma is devoted to advancing its therapeutic offerings. One of its other innovative products, CannEpil®, has recently gained attention within the medical community. CannEpil® is an oral mucosal solution containing a high-CBD, low-THC formulation. Designed primarily to lower the frequency and severity of seizures, CannEpil® allows patients to enjoy a better quality of life without significant psychoactive effects.

The successful development and increasing adoption of CannEpil® in the UK illustrate Argent BioPharma's resolve to address global health challenges associated with epilepsy and other complex neurological disorders. This line of therapies complements the company's goal to innovate and provide solutions where they are most needed.

Continued Commitment to Innovation

As Argent BioPharma moves forward, the absolute focus remains on developing treatments that are not only innovative but also represent a significant step toward solving unmet medical needs. With CimetrA® and CannEpil® at the forefront, the company is poised to make vital contributions to the future of healthcare.

Contact Information

For further information about Argent BioPharma and its breakthrough therapies, please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
Phone: +61 8 6555 2950

Argent BioPharma
Rowan Harland
Company Secretary
Phone: +61 8 6555 2950

Frequently Asked Questions

What is CimetrA®?

CimetrA® is a novel anti-inflammatory treatment recently developed by Argent BioPharma, showing promising results in clinical trials for various inflammatory diseases.

How did CimetrA® perform in clinical trials?

The Phase IIb clinical trial demonstrated a strong safety profile and faster recovery times for COVID-19 patients compared to placebo.

What are the key benefits of using CimetrA®?

CimetrA® offers improved clinical outcomes, reduced inflammation, and enhanced quality of life for patients suffering from inflammatory diseases.

What other products does Argent BioPharma offer?

Besides CimetrA®, Argent BioPharma has developed CannEpil®, an oral mucosal solution aimed at controlling seizures in epilepsy patients.

How does Argent BioPharma ensure patient safety?

Argent BioPharma prioritizes patient safety and well-being throughout the clinical trial process, strongly focusing on developing treatments with minimal adverse effects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 168

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 249

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 194

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
Dana Concludes Tender Offers for Senior Notes

Updated Category News Views 130

An Investor's Glance at Dana's Strategic Moves Dana Incorporated (NYSE: DAN) just pulled a bold move with their tender offers, snapping up a hefty $357,873,000 in outstanding principal on their senior notes. This isn’t just pocket change; folks holding out for securities can feel the tension of watching big numbers get shuffled around. You gotta wonder, what's the play...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 95

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Chime Joins S&P MidCap 400 Amid Merger Jostle

Updated Category News Views 194

Index Shake-Up: Who's In, Who's Out? Hold onto your hats, folks—big changes are coming to the S&P MidCap 400! Chime Financial Inc. is crashing the party, taking a seat at the table, as NorthWestern Energy Group gets the boot. Now, if that doesn’t grab your attention, I don’t know what will. You've got to appreciate the chaos and opportunities that come with a roster...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 161

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 186

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading

Top 5 Most Recently Viewed Articles

Carvana Integrates Auction-IRC Megasite in Atlanta Area

Updated Category News Views 150

Carvana's Exciting New Megasite Integration in Atlanta Carvana Co. (NYSE: CVNA), a leading online platform for buying and selling used cars, has made an announcement that showcases its commitment to innovation and growth. The company is integrating an auction and reconditioning 'Megasite' in the Atlanta area. This strategic move aims to enhance operational efficiency...

Continue Reading
Skyflow Introduces Enhanced Security Layer for Agentic AI

Updated Category News Views 201

Skyflow's Approach to Agentic AI Security Skyflow has emerged as a leader in the realm of data security and privacy, especially within the rapidly evolving landscape of artificial intelligence. The company has recently unveiled exciting enhancements to its Agentic AI offerings. These advancements are designed to allow businesses to deploy AI agents while ensuring robust...

Continue Reading
Bladex Achieves Impressive Financial Growth in Q3 2025 Results

Updated Category News Views 213

Bladex Reports Remarkable Financial Performance Bladex has announced impressive financial results for the third quarter of 2025, highlighting exceptional growth in its Commercial Portfolio, which surged to US$10.9 billion, reflecting a 12% increase year-over-year. Additionally, total deposits reached US$6.8 billion, a significant 21% growth compared to the previous year....

Continue Reading
First Trust Advisors L.P. Distributes Monthly ETF Earnings

Updated Category News Views 119

First Trust Advisors L.P. Announces ETF Distributions First Trust Advisors L.P. (FTA) has declared its monthly distributions for various exchange-traded funds. This announcement brings exciting news for investors as FTA continues to showcase its commitment to providing transparent and regular distributions. Important Distribution Dates In connection with the recent...

Continue Reading
Tungsten Prices Surge: Almonty Industries Weighs Future Trends

Updated Category News Views 402

A New Dawn for Tungsten Pricing Forget the old narratives; tungsten is strutting its stuff like never before. Almonty Industries Inc. (NASDAQ:ALM) is at the forefront—CEO Lewis Black sat down recently to chat with Benzinga, and his insights really hit home. We're staring down a supply squeeze like nothing we've seen before, echoing through both Eastern and Western...

Continue Reading